Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07805850Recruiting
Balance training for people with multiple sclerosis
This study tests different ways of monitoring balance exercises during a rehabilitation stay to see which is more effective and feasible. It may help improve balance and safety in daily life for people with MS.
Valens, Canton of St. GallenAges 18 years+ - NCT07807228Recruiting
Skin microbiome changes with lebrikizumab for eczema
This study looks at how lebrikizumab, a biologic medicine for atopic dermatitis (eczema), affects the skin's microbiome (the natural community of microorganisms on your skin). It aims to see if changes in the skin's microbiome are linked to treatment response.
CopenhagenAges 18 years+ - NCT07807280Recruiting
Learning carb counting with a continuous glucose monitor
This study tests a new way to learn carb counting using a continuous glucose monitor (CGM). It may help you improve your blood sugar control without needing more injections.
Los Angeles, CaliforniaAges 18 years+ - NCT07802678RecruitingPhase 4
Stopping RA medicines in combination therapy
This study looks at whether people with rheumatoid arthritis who are stable on a TNF inhibitor plus another drug can safely stop the second drug. It aims to see if stopping the extra medicine keeps the disease under control and reduces side effects.
Nijmegen, GelderlandAges 18 years+ - NCT07808827RecruitingPhase 3
New targeted drug plus chemo for large b-cell lymphoma
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07804849RecruitingPhase 2/Phase 3
Verapamil for newly diagnosed type 1 diabetes in youth
This study tests whether an oral blood pressure medicine called verapamil can help preserve insulin-making cells in children and teens recently diagnosed with type 1 diabetes. It may slow the disease and reduce how much insulin you need.
CairoAges 10–18 - NCT07801625Recruiting
How eyes and nose react to grass allergy
This study looks at how people with and without grass allergies react when a small amount of grass allergen is put into the eye. It aims to understand the immune response in the eyes and nose, which may help improve allergy treatments.
Kingston, OntarioAges 18–70 - NCT07803978Enrolling by invitationEarly Phase 1
Study of Amimaitosai plus steroids for gut graft-versus-host disease
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+ - NCT06005298Recruiting
Testing SBIRT to help with PrEP and alcohol use
This study looks at whether talking about alcohol use can help people stick with their PrEP routine. It tests a simple program called SBIRT (Screening, Brief Intervention, and Referral to Treatment) to support your health and HIV prevention.
Louisville, KentuckyAges 18–85 - NCT06513247Recruiting
Screening for type 1 diabetes in high-risk relatives
This study screens high-risk children for early signs of type 1 diabetes by testing relatives who already have the condition. It aims to catch diabetes early so treatment can start sooner.
RiyadhAges 2–18 - NCT06513234RecruitingPhase 2
Orelabrutinib and Obinutuzumab for untreated marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
TianjinAges 18 years+ - NCT04014374Recruiting
Safety study for stem cell transplant after mogamulizumab
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Milwaukee, WisconsinAges 18 years+ - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT05219903Recruiting
Study of children with eosinophilic gut disorders
This study looks at children ages 0–18 with eosinophilic gut disorders (EGIDs) to better understand these conditions and how they are managed. It may help doctors improve care by comparing real-world information from patients followed at participating hospitals.
PaviaAges birth–18 years - NCT07800871RecruitingPhase 1/Phase 2
FT839 cell therapy for autoimmune diseases
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Fullerton, CaliforniaAges 18–70 - NCT07800104RecruitingPhase 1
Study of a new pill for moderate-to-severe eczema
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 1.5 years–65 years - NCT07799207Recruiting
Daily yogurt and immune health in healthy adults
This study tests whether eating yogurt every day can help your immune system work better and make you feel healthier overall. You would eat a provided yogurt daily for the study period and attend a few check-ins.
Chicago, IllinoisAges 18–65 - NCT04837859RecruitingPhase 2
Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
CologneAges 18 years+ - NCT06520176RecruitingPhase 3
Comparing two stem cell collection methods for multiple myeloma
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Dongyang, ZhejiangAges 18–75 - NCT06523478Recruiting
Tonsil injection allergy shots for hay fever
This trial tests a new way to treat allergies by injecting allergy medicine directly into the tonsils. It may help people with hay fever who haven't gotten relief from standard treatments or want to avoid long-term medication.
Wuhan, HubeiAges 5–65 - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.